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Introduction: To evaluate myocardial strain and extracellular volume in myotonic
dystrophy type 1 (DM1) patients as potential imaging biomarkers of subclinical
cardiac pathology.
Materials andmethods: We retrospectively analyzed 9 DM1 patients without apparent
cardiac disease who had undergone cardiac magnetic resonance at our center. Patients
were age- and sex-matched with healthy controls. The Mann-Whitney U test was used
to compare cardiac strain between the two groups. The t-test was used to compare the
extracellular volume obtained in DM1 patients with that in healthy subject. Spearman’s ρ
was used for studying the associations among imaging parameters.
Results: Global cardiac strain (median−19.1%; IQR−20.5%,−16.5%) in DM1 patients
was lower (p = 0.011) than that in controls (median−21.7%; IQR−22.7%,-21.3%).
Global extracellular volume in DM1 patients (median 32.3%; IQR 29.3%,36.8%) was
significantly (p = 0.008) higher than that reported in literature in healthy subjects (median
25.6%; IQR 19.9%,31.9%). Global cardiac strain showed a strong, positive correlation
with septal strain (ρ = 0.767, p = 0.016) and with both global (ρ = 0.733 p = 0.025)
and septal extracellular volume (ρ = 0.767, p = 0.016).
Discussion: The increase in cardiac extracellular volume and decrease in strain are
signs of early cardiac pathology in DM1. Physicians dealing with DM1 may take into
consideration cardiac magnetic resonance as a screening tool to identify early cardiac
involvement in this condition.
Keywords: myotonic dystrophy, cardiac magnetic resonance, myocardial strain imaging, extracellular volume,
cardiac fibrosis
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INTRODUCTION
Myotonic dystrophy type 1 (DM1) is a dominantly inherited
neuromuscular rare disorder caused by a mutation (CTG repeat
expansion) in the the Dystrophia Myotonic Protein Kinase
gene that affects 1:8,000 people worldwide (1–4). Cardiac
involvement in DM1 occurs in up to 80% of the cases
(5, 6), and represents the second most common cause of
death in this population, straight after respiratory failure (7).
According to current recommendations (8), DM1 patients
should be periodically screened for cardiac disease with
electrocardiography and echocardiography.
Autoptic examinations of DM1 hearts revealed fibrous tissue
infiltration in the conduction system (9) which may cause
arrhythmias. However, electrocardiography detects onlymanifest
arrhythmias related to large patches of localized fibrosis, while
echocardiography may be hindered by bad acoustic window
quality or motion impairment in severe patients.
A viable alternative to these techniques is cardiac magnetic
resonance (CMR), which allows to assess both localized
and diffuse fibrosis through the analysis of late gadolinium
enhancement (LGE) and the calculation of extracellular volume
(ECV) with T1-mapping (10, 11) even before the onset of clinical
manifestations of heart arrhythmias. Moreover, CMR allows for
the calculation of functional parameters such as cardiac strain,
an indicator of cardiac contractility, which can be impaired when
the myocardium is fibrotic or degenerated (12). Cardiac strain
can also be obtained through echocardiography (13, 14) and
serve as a predictor of cardiovascular events in asymptomatic
DM1 patients (15). However, a study by Khan et al. (16) showed
that strain parameters obtained at CMR are more reliable and
reproducible than those obtained at echocardiography due to
high dependence on the operator and lower acoustic window
quality of the latter technique compared to the former.
Few studies have assessed DM1 cardiac involvement using
CMR. Petri et al. (17) and Turkbey et al. (18) reported LGE
and T1 alterations in patients with advanced cardiac disease.
Hermans et al. (19) observed the presence of subclinical
cardiomyopathy in DM1 patients through LGE evaluation,
stating that their cardiac involvement may be overlooked if
screened with electrocardiography alone. However, Petri et al.
(17) showed that LGE is only detectable in case of focal fibrosis,
while ECV may identify diffuse fibrosis, which may be present
in patients at earlier stages of cardiac involvement, potentially
preceding localized fibrosis.
Evidence of subclinical cardiac pathology in asymptomatic
DM1 patients come also from basic research studies (20–
22). Recently, Valaperta et al. (20) found that blood levels of
circulating cardiac Troponin T (cTnT), a serological biomarker
of cardiac injury, were significantly higher in asymptomatic DM1
patients compared to healthy subjects. The authors observed
that the rise in circulating cTnT was more likely due to
Abbreviations: DM1, myotonic dystrophy type 1; CMR, cardiac magnetic
resonance; LGE, late gadolinium enhancement; ECV, extracellular volume; cTnT,
cardiac Troponin T; MRC, medical research council; MIRS, muscular impairment
rating scale; CS, cardiac strain.
subclinical myocardial damage, which had not been detected by
conventional measures, rather than being caused by a release
of cTnT from injured skeletal muscle into the blood pool, as
observed in other neuromuscular diseases (20–22).
In light of these considerations, the aim of our study was to
evaluate ECV and strain on CMR in DM1 patient and appraise
whether they could be viable imaging-biomarkers of subclinical
cardiac pathology. Secondly, we evaluated if there were some
associations between imaging parameters and data stemming
from clinical assessment and laboratory testing.
MATERIALS AND METHODS
Study Design and Population
The local Ethics Committee approved this study (Ethics
Committee of San Raffaele University Hospital; protocol code
CardioRetro; approved on March 9th, 2017). This research
received no specific grant from any funding agency in the public,
commercial or not-for-profit sectors. Due to the retrospective
nature of this study specific informed consent was waived.
We retrospectively analyzed images of asymptomatic DM1
patients who had undergone a CMR examination as screening
test for early cardiac involvement at our cardiovascular referral
center (IRCCS Policlinico San Donato, University Hospital)
between November 2014 and July 2016. Three out of nine
patients were taking mexiletine at the time of the examination.
Additional inclusion criteria were:
- Diagnosis of DM1 through genetic testing, based upon
the clinical diagnostic criteria set by the International
Consortium for Myotonic Dystrophy (23); DM1 genotyping
was performed on genomic DNA extracted from peripheral
blood leukocytes (24).
- Presence of a complete set of short-axis cine sequences.
- Presence of both native and post-contrast T1 maps.
We excluded patients who had a low (≤50%) ejection fraction, or
who presented overt symptoms or signs of cardiac pathology and
thus would not represent the ideal population for screening early
cardiac damage.
Each patient was age- and sex-matched with a healthy control
to compare the strain analysis to that of patients. Controls were
chosen among subjects who had been referred to CMR for a more
thorough investigation of isolated supraventricular extrasystoles.
Such individuals had a negative CMR examination and did not
present significant extrasystoles during the examination, thus
yielding excellent image quality. None of our controls had been
referred for ablation.
Neuromuscular Assessment and Serum
Biomarkers
According to clinical practice, as a part of their routine
management, DM1 patients had undergone a baseline and
routine clinical neuromuscular examination. Single muscular
group and global strength were manually quantified according
to the medical research council (MRC) scale (25), which assesses
seven muscular groups, grading strength from 0 to 5 in each one,
for a score total of 130.
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Global muscular impairment in DM1 patients was also
evaluated using the muscular impairment rating scale (MIRS)
(26), which grades global motor impairment from 5 to
0, which correspond, respectively to the least and most
functional impairment.
Moreover, DM1 patients had undergone routine blood tests
which included genetic test.
Cardiological Assessment
According to clinical practice, all DM1 patients had undergone
a 12-lead baseline electrocardiogram (EKG) and a 24-h Holter-
EKG to detect potential cardiac involvement. The duration of
QRS complex, PR, QTc interval, and eventual bouts of atrial
fibrillation were also registered.
A transthoracic 2D-echocardiogram had been performed
in DM1 patients, and data regarding the ejection fraction
was collected.
Image Assessment
All CMR examinations were performed using a 1.5-T Magnetom
Aera unit (Siemens Medical Solutions, Erlangen, Germany),
with 45-mT/m gradient power. Examinations were performed
using a 12-channel surface phased-array coil, placed over the
thorax of the patient in supine position. Image acquisition was
electrocardiographically gated.
Every CMR study included a complete set of short-axis (from
base to apex) cine images, using an electrocardiographically
triggered steady-state free precession pulse sequence acquired
with the following technical parameters: time of repetition
(TR)/time of echo (TE) 4.0/1.5ms; flip angle 80◦; slice thickness
8mm; time resolution 45ms; mean acquisition time 14 ± 4 s
(mean ± standard deviation), number of phases 30, in-plane
pixel size 1.40× 1.80 mm2.
A native MOLLI sequence with 5(3)3 protocol was acquired
at basal, mid, and apical-ventricular level in short-axis view
in systole, by starting the data acquisition at an individually
adapted trigger time. The MOLLI sequence included motion
correction and subsequent automatic generation of T1 maps.
MOLLI sequences were acquired with the following parameters:
TE/TR 1.12 ms/2.8ms; flip angle 35◦; bandwidth 1,085 Hz/pixel;
in-plane pixel size 1.40× 1.80 mm2, parallel imaging factor 2.
Using softwares from the Medis suite (Medis Medical
Imaging Systems, Leiden, The Netherlands), the endocardium
and epicardium of the left ventricle were manually segmented
on cine images. Circumferential strain (CS) was subsequently
calculated both globally and for each cardiac segment; Controls
CMR examinations included cine evaluation with the same
sequence used for patients.
Left ventricle global ECV was calculated from T1 values of
different, manually traced, regions of interest on different cardiac
regions (namely anterior, lateral, posterior and septal), at LV
mid-level, in native and post-contrast T1 maps, considering
patient hematocrit values. Since ECV lacks a reference range
for healthy subjects, the Society of Cardiovascular Magnetic
Resonance recommends comparing patient ECV values with
those from previous studies where the same systemwas used (27).
Therefore, the ECV obtained from DM1 patients was compared
with that of healthy subjects reported in the meta-analysis by
Sardanelli et al. (28).
Statistical Analysis
Normal data distributions were reported as mean ± standard
deviation, while non-normal data distributions were reported as
median and interquartile range (IQR). The minimum and the
maximum value of each distribution were also reported.
Differences between independent distributions were evaluated
using Mann-Whitney U test, while correlations were evaluated
using Spearman’s ρ. The t-test was used to compare the global
ECV obtained in our DM1 patients with that published in
literature by Sardanelli et al. (28) in healthy subjects.
Statistical analysis was performed using SPSS (IBM SPSS Inc.,
Chicago, IL, USA), and p-values lower than 0.05 were considered
as significant.
RESULTS
Study Population
A total of nine DM1 patients (6 females and 3 males) retrieved
from our database were analyzed and matched for sex and age
with nine controls. The median age at onset of DM1 in our
patients was 20 (IQR 18–35) years, and the median age at the day
of the examination was 36 (IQR 29–44) years. As required by the
inclusion criteria, all of them are affect by DM1 and the length of
the CTG repeat mutation ranged from 300 to 1,000 base pair.
The median age of our controls at the day of the examination
was also 36 (IQR 29–44) years.
Raw data and distribution characteristics of our nine DM1
patients are reported in Table 1. Raw data of our controls are
shown in Table 2.
Neuromuscular Assessment
The median value of MRC scale in DM1 patients was 126 (IQR
112–130) points with a distribution that ranged from 103 to 130
points. A negative correlation between MRC scale and the age at
the examination was found (ρ =−0.809, p= 0.008).
Concerning theMIRS scale, the median score was 3 (IQR 2–4)
points with a distribution which ranged from 2 to 5 points. In this
case, a positive correlation was found betweenMIRS scale and the
age of onset of DM1 in our patients (ρ = 0.687, p= 0.041).
In all DM1 patients clinical myotonia was absent at the day of
the examination.
Moreover, no correlations were found between the genetic test
and all the others parameters collected.
Cardiological Assessment
The median heart rate was 71 (IQR 69–73) bpm with a
distribution which ranged from 65 to 73 bpm. This value showed
a very strong, negative correlation (ρ = −0.821, p = 0.007)
with PR (median 174, IQR 144–194; range 140–233) ms and (ρ
= −0.687, p = 0.041) with QRSD (median 105, IQR 102–110;
range 82–138) ms.
The median value of QTc was 439ms (IQR 415–447; range
402–470) ms, and positive correlations were found with the age
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TABLE 2 | Raw imaging data of our control group.
Age at CMR (y, range) CMR assessment
GCS
(%)
SCS
(%)
Patient 1 50–54 −17. 7 −27. 6
Patient 2 25–29 −21. 7 −24. 2
Patient 3 20–24 −23. 4 −27. 0
Patient 4 40–44 −21. 3 −16. 9
Patient 5 50–54 −22. 5 −22. 6
Patient 6 35–39 −22. 7 −28. 3
Patient 7 30–34 −19. 3 −18. 8
Patient 8 25–29 −21. 3 −18. 3
Patient 9 35–39 −23. 9 −26. 7
Median 36 −21.7 −24.2
IQR 29–44 −22.7 to −21.3 −27.1 to −18.8
Min-max 24–53 −23.9 to −17.7 −28.3 to −16.9
CMR, cardiac magnetic resonance.
of onset (ρ = 0.785, p = 0.012) and the age at the examination
(ρ = 0.667, p= 0.05).
Imaging Assessment
Patients’ global CS (median −19.1%, IQR −20.5%, −16.5%;
range −21.7 to −13.9%) was lower (p = 0.011) than that in
controls (median−21.7%, IQR −22.7%, −21.3%; range −23.9
to−17.7%).
Patients’ septal CS (median −20.3%, IQR −24.0%, −17.9%;
range −24.4 to −14.7%) was not significantly different (p =
0.113) that in controls (median −24.2%, IQR −27.1%, −18.8%;
range −23.9 to −17.7%). Septal CS negatively correlated with
QTc (ρ =−0.733, p= 0.025).
Concerning ECV, global ECV was 32.3% (IQR 29.3, 36.8%)
in DM1 patients with values that ranged from 27.2 to 43.2%;
while septal ECV was 31.9% (IQR 30.1, 37.6%) with values which
ranged from 26.9 to 39.2%. Moreover, the global ECV obtained
in our DM patients was significantly (p = 0.008) higher than
that (25.6%, IQR 19.9–31.9%) reported in literature (28) for
healthy subjects.
Global CS showed a strong, positive correlation with septal CS
(ρ = 0.767, p= 0.016) and with both global (ρ = 0.733 p= 0.025)
and septal ECV (ρ = 0.767, p = 0.016). A very strong positive
correlation was observed between global ECV and septal ECV
(ρ = 0.983, p< 0.001). Further details are shown in Figures 1, 2.
Albeit not statistically significant, a positive correlation
was found between global ECV and the MIRS score
(ρ = 0.621, p= 0.74).
DISCUSSION
The aim of our study was to evaluate ECV and strain on CMR in
myotonic DM1 patient and appraise whether they could be viable
imaging-biomarkers of subclinical cardiac pathology. Moreover,
the secondary aim was to evaluate if there were some associations
Frontiers in Neurology | www.frontiersin.org 4 March 2020 | Volume 11 | Article 192
Alì et al. CMR Risk Assessment in DM1
between imaging parameters and data stemming from clinical
assessment and laboratory testing.
Thus, while at least some of the results (e.g., correlation
between muscle impairment and the age of onset or between the
ECG values) were expected or lacking clinical relevance, there are
instead some main CMR findings that we believe might be useful
to evaluate the subclinical condition of DM1 patients which we
will discuss below.
Our global CS values were significantly lower in
patients than in controls (p = 0.011), suggesting that
contractility seems to be impaired in patients even in the
absence of clinical dysfunction. The lack of a significant
difference for septal CS between patients and controls
may be due to the small population involved in the study.
Indeed, segmental CS is more subject to error than global
FIGURE 1 | Boxplot showing the comparison of circumferential strain (CS)
values in healthy controls vs. myotonic dystrophy (DM) patients.
CS, since it depends both on contouring and reference
points identification.
We compared ECV of our patients with that of healthy
subjects reported in the meta-analysis published by Sardanelli
et al. (28). The authors obtained a pooled ECV of 25.6%
(IQR 19.9%−31.9%), resulting significantly lower (p = 0.008)
compared to our ECV value of 32.3% (IQR 29.3, 36.8%).
Therefore, we hypothesize that there may be a certain degree of
subclinical diffuse fibrosis in the left ventricle of DM1 patients.
A similar finding was reported by Schmacht et al. (29) on a
population of myotonic dystrophy type 2 patients. The authors
showed an increased ECV in positive LGE patients, confirming
focal fibrosis, but also an increased ECV at the adjacent medial
inferolateral segment without focal fibrosis detected by LGE.
These results may indicate the occurrence of diffuse progressive
fibrosis in these genetic conditions.
The positive correlation between both global and septal ECV
and global CS may signify that contractile impairment in DM1
patients is due to fibrosis. The persistence of a significant
correlation only at the septummay suggest that this phenomenon
is more represented at septal level than in other areas. This
agrees with previous pathological studies conducted on DM1
patients, which found the septum to be more prone to fibrosis
than other left ventricular zones (9). Furthermore, a study
by Garcia et al. (15) states that impaired strain obtained by
echocardiography may be a predictor of adverse events in
DM1 patients. We may thus hypothesize the same to be true
for CMR-derived strain, since a strong correlation between
CMR and echocardiographic strain values has already been
proven (30).
Our study has some limitations, the most important being its
small sample size and its retrospective design, which draw the
need for prospective studies on bigger samples. However, we have
to consider the prevalence of DM1 in the general population that
makes, also in a reference center as our institution, DM1 patients
FIGURE 2 | Linear regression plot representing the correlation between both global (GECV) and septal extracellular volume (SECV) and global circumferential strain
(GCS) in myotonic dystrophy patients.
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difficult to find. Moreover, the fact that control subjects were
lacking sequences for T1 mapping did not allow the calculation
of ECV in this sample, thus leading to the need to rely on values
obtained from external studies. Nevertheless, the normality
values for ECV were assessed according to recommendations
from the Society for Cardiovascular Magnetic Resonance (27).
This may indeed present as a source of bias, even though ECV
values, differently from T1 mapping results, have proven robust.
Further prospective studies dedicated to the confirmation and
in-depth analysis of the findings from this work should indeed
address this limitation. Another further limitation is represented
by the fact that this study only included the assessment of
circumferential strain and did not appraise longitudinal or
radial strain. Longitudinal strain was not calculated since not
all patients had all the necessary acquisitions for its estimation,
namely long-axis, 2-, 3-, and 4-chamber cine sequences. Radial
strain was not included in the study because it has shown
subpar reproducibility in previous analyses (31). Conversely,
circumferential strain only requires short-axis cine sequences
which were available in all patients and has shown satisfactory
reproducibility in previous studies. Additionally, reproducibility
of ECV was not appraised in this study due to the small
study sample. Nevertheless, previous studies have observed an
excellent inter-reader and inter-system reproducibility of ECV
measurements (32).
We tested our sample ECV (median age 36 years old) with
the one reported in the meta-analysis by Sardanelli et al. (28)
which comprised subjects whose age ranged from 15 to 68.
Given the slight but positive correlation between ECV and age,
the point estimate provided by Sardanelli et al. (28) might
overestimate the one for an ideal sample of 36 years old healthy
subjects. Although this is a limitation to our study, we used this
conservative approach since lower ECV values for controls would
result into stronger statistical significance when tested against our
patients ECV.
Our preliminary results suggest that in DM1 patients without
apparent cardiac disease, the increase in ECV and decrease
in CS may be taken into consideration as a trigger for
follow-up and implementation of preventive measures. Our
results are also consistent with those reported by Luetkens
et al. (33) and Chmielewski et al. (34) who investigated the
role of CMR in DM1. The first found lower myocardial
strain and higher ECV in 13 DM1 patients compared to
controls. The second reported similar results and found LGE
presence to be independently associated with the occurrence of
arrhythmic episodes. Therefore, we believe physicians dealing
with DM1 patients may take into consideration CMR as an
early screening tool to identify initial cardiac involvement in
this condition.
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